Program
daromun
Also written as “L19IL2/L19TNF” and “Daromun”.
Its studies are mostly in Carcinoma, Basal Cell · Melanoma, led by Philogen.
Furthest: phase 3, since May 18, 20186 company-led studies, 6 open or runningNext primary completion: Dec 2027 (phase 3)
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Philogen | 66 open or running | phase 3since May 18, 2018 | May 18, 2018 | Dec 2027phase 3 · NCT03567889 |
Also a collaborator on its studies: Merck.
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- May 18, 2018First study: phase 3 study in MelanomaFirst studyNCT03567889 · 186 planned · United States, Spain, Switzerland
- Apr 7, 2022Phase 2 study in Carcinoma, Basal CellNCT05329792 · 70 planned · France, Italy, Spain
- Jan 26, 2024Phase 2 study in MelanomaNCT06284590 · 162 planned · United States, Germany, Italy
- Nov 7, 20253 phase 2 studiesNCT07228442, NCT07227870, NCT07227350
Ahead
- Dec 2027Primary completion: phase 3 study in MelanomaNCT03567889
- Jul 2028Primary completion: phase 2 study in MelanomaNCT06284590
- Feb 2031Primary completion: phase 2 study in Locally Advanced Cutaneous Squamous Cell CarcinomaNCT07228442
- Feb 2031Primary completion: phase 2 study in Carcinoma, Basal CellNCT07227870
TargetBeta
IL2 →read by rule
“A combination of darleukin (L19-IL2), an immunocytokine consisting of the recombinant form of interleukin-2 (IL-2), ”NCIt, by rule
Other programs on IL2
| Program | Company | Furthest phase | Studies |
|---|---|---|---|
| darleukinrule | Philogen | phase 3 | 9 |
| Daxokafusp Alfa | Sanofi | phase 2 | 2 |
| SAR444336 | Sanofi | phase 2 | 2 |
| Anti-PD-1/IL-2 Fusion Protein TEV-56278 | Teva Pharmaceutical Industries | phase 1 | 2 |
| IL-2 Mutein/Fc Fusion Protein HM16390rule | Hanmi Pharmaceutical | phase 1 | 1 |
| Autologous IL-2-expressing Anti-mesothelin CAR T-cells OPB-101rule | outpace-bio-inc | phase 1 | 1 |
Studies
All 6 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT07228442Locally Advanced Cutaneous Squamous Cell Carcinoma · United States, Germany, Greece and more | 2 | Recruiting | Feb 2031 | 92 |
| NCT07227870Carcinoma, Basal Cell · United States, Germany, Greece and more | 2 | Recruiting | Feb 2031 | 92 |
| NCT07227350Carcinoma, Basal Cell · United States, Germany, Greece and more | 2 | Recruiting | Feb 2031 | 180 |
| NCT06284590Melanoma · United States, Germany, Italy | 2 | Recruiting | Jul 2028 | 162 |
| NCT05329792Carcinoma, Basal Cell · France, Italy, Spain | 2 | Recruiting | Jun 2024 | 70 |
| NCT03567889Melanoma · United States, Spain, Switzerland | 3 | Recruiting | Dec 2027 | 186 |
How it is read
Names in the registry
- “L19IL2/L19TNF”, 5 entries
- “Daromun”, 1 entry
Conditions, from the studies’ own filings
- Carcinoma, Basal Cell, 3 studies
- Melanoma, 2 studies
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.